Trial Profile
A drug interaction study of a novel P38 MAP kinase inhibitor with methotrexate in rheumatoid arthritis patients.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Feb 2010
Price :
$35
*
At a glance
- Drugs Pamapimod (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Registrational
- Sponsors Roche
- 25 Jan 2010 Results were published in the Journal of Clinical Pharmacology.
- 26 Sep 2009 New trial record.